THERAPY DOSSIER · th-dc65555a0049

Dodeca-2E,4E,8Z,10Z(E)-tetraenoic acid isobutylamides (alkamides Alk-8/9) isolated from Echinacea purpurea roots

Nutraceutical · Botanical (isolated Echinacea purpurea alkamides Alk-8/9); isolated alkamides not trialed (only whole Echinacea preparations)

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Botanical (isolated Echinacea purpurea alkamides Alk-8/9); isolated alkamides not trialed (only whole Echinacea preparations)
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 21985290 ↗2011Reported benefit

Echinacea alkamides prevent lipopolysaccharide/D-galactosamine-induced acute hepatic injury through JNK pathway-mediated HO-1 expression.

MouseEndotoxin/LPSICRMale

Model: Acute fulminant hepatitis induced by lipopolysaccharide plus D-galactosamine; complemented by lipopolysaccharide-stimulated murine macrophages in vitro

Alkamides Alk-8/9 dose-dependently induced haem oxygenase-1 in lipopolysaccharide-stimulated macrophages via JNK signalling, and in lipopolysaccharide/D-galactosamine treated mice they markedly induced hepatic c-jun and haem oxygenase-1 while suppressing serum aminotransferase activities, tumour ne…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…